Stoke Therapeutics to Present at Upcoming Investor Conferences in June
03 Giugno 2024 - 10:30PM
Business Wire
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
dedicated to addressing the underlying cause of severe diseases by
upregulating protein expression with RNA-based medicines, today
announced that management will present at the following upcoming
investor conferences:
Goldman Sachs 45th Annual Global Healthcare Conference
Date: Monday, June 10, 2024 Time: 4:00 p.m. ET
TD Cowen Genetic Medicines & RNA Summit Date:
Thursday, June 20, 2024 Time: 10:00 a.m. ET
Live webcasts of each event and an archived replay of the
webcasts following each event, will be available on the Investors
& News section of Stoke’s website at
https://investor.stoketherapeutics.com/.
About Stoke Therapeutics Stoke Therapeutics (Nasdaq:
STOK), is a biotechnology company dedicated to addressing the
underlying cause of severe diseases by upregulating protein
expression with RNA-based medicines. Using Stoke’s proprietary
TANGO (Targeted Augmentation of Nuclear Gene Output) approach,
Stoke is developing antisense oligonucleotides (ASOs) to
selectively restore protein levels. Stoke’s first compound,
STK-001, is in clinical testing for the treatment of Dravet
syndrome, a severe and progressive genetic epilepsy. Dravet
syndrome is one of many diseases caused by a haploinsufficiency, in
which a loss of ~50% of normal protein levels leads to disease.
Stoke is pursuing the development of STK-002 for the treatment of
autosomal dominant optic atrophy (ADOA), the most common inherited
optic nerve disorder. Stoke’s initial focus is haploinsufficiencies
and diseases of the central nervous system and the eye, although
proof of concept has been demonstrated in other organs, tissues,
and systems, supporting its belief in the broad potential for its
proprietary approach. Stoke is headquartered in Bedford,
Massachusetts with offices in Cambridge, Massachusetts. For more
information, visit https://www.stoketherapeutics.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240603791457/en/
Stoke Investor Contact: Eric Rojas Vice President,
Investor Relations IR@stoketherapeutics.com 617-312-2754
Grafico Azioni Stoke Therapeutics (NASDAQ:STOK)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Stoke Therapeutics (NASDAQ:STOK)
Storico
Da Giu 2023 a Giu 2024